MREO Alexandra Hughes-wilson sells $214K worth of shares
Sep 17, 2024, 1:34 AM
13.50%
What does MREO do
Mereo BioPharma Group Plc develops therapeutics for oncology and rare diseases, focusing on setrusumab for osteogenesis imperfecta and alvelestat for alpha-1-antitrypsin deficiency. The company also has oncology candidates and partnered programs like Navicixizumab.
Alexandra Hughes-wilson sold 47,798 shares of MREO on 12 September at $4.47 per share, worth a total of $214K. They now own 190,816 MREO shares, or a 24% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
